SaaS entity
All 1 tracked stories fall under one category: earnings. Acadia Pharmaceuticals is most often covered alongside Alkami Technology, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 3.9 for the broader beat in this window.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Acadia Pharmaceuticals is most often covered alongside Alkami Technology, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 3.9 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6.5 for that window. Acadia Pharmaceuticals appears in 1 tracked SaaS story from February 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 50 SaaS stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Acadia Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Alkami Technology reported strong Q4 2025 results, highlighting a significant shift toward cloud-native digital banking platforms among regional financial institutions. The company's performance, alongside ACADIA Pharmaceuticals' commercial growth, underscores a resilient market for specialized SaaS and high-margin healthcare solutions.
Acadia Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
